Strategic Delay and Bargaining Over Public Insurance Coverage for Drugs in Australia

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Health Technology Assessment

Background:

• Public funding for pharmaceuticals involves complex negotiations between manufacturers and agencies.
• Empirical research on the economic structure and timing of these pharmaceutical pricing negotiations is limited.

Purpose of the Study:

• To analyze how negotiation timing reflects the economic structure of pharmaceutical pricing agreements.
• To assess if observed delays and agreements align with dynamic bargaining theory under incomplete information.

Main Methods:

• Utilized a duration model to analyze Australian pharmaceutical negotiation data from 2005 to 2018.
• Examined 634 submissions for 400 therapies, focusing on negotiation duration and agreement rates.

Main Results:

• Agreements took a median of 16 months, with 71% of negotiation rounds ending without immediate agreement.
• Therapies with lower perceived value (higher cost per QALY, budget impact, evidence uncertainty) faced longer delays and lower agreement rates.
• Therapies with high clinical importance, perceived need, or public interest were listed faster.

Conclusions:

• Observed negotiation patterns suggest a systematic rule where therapies are funded if expected health gains justify opportunity costs.
• The timing of pharmaceutical pricing agreements reflects strategic negotiation under uncertainty, rather than mere procedural delays.